Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis.

van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE.

J Rheumatol. 2014 Sep;41(9):1843-8. doi: 10.3899/jrheum.131289. Epub 2014 Aug 1.

PMID:
25086071
2.

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H.

Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008.092585. Epub 2008 Jul 28.

3.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
4.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

5.

Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis.

Yazgan S, Celik U, Işık M, Yeşil NK, Baki AE, Şahin H, Gencer E, Doğan İ.

Int Ophthalmol. 2017 Feb;37(1):139-145. doi: 10.1007/s10792-016-0239-y. Epub 2016 May 6.

PMID:
27154720
6.

Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.

Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A.

Eye (Lond). 2000 Jun;14 ( Pt 3A):340-3.

PMID:
11026996
7.

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.

Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP.

Arthritis Rheum. 2007 Aug 15;57(6):1050-7.

8.

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).

Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr; ATLAS Study Group.

J Rheumatol. 2008 Jul;35(7):1346-53. Epub 2008 May 15. Erratum in: J Rheumatol. 2011 Apr;38(4):788.

PMID:
18484692
9.

Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.

Fabiani C, Vitale A, Lopalco G, Iannone F, Frediani B, Cantarini L.

Clin Rheumatol. 2016 Nov;35(11):2631-2638. Epub 2016 Sep 30. Review.

PMID:
27686662
10.

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.

Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, Tak PP, Baeten DL.

Ann Rheum Dis. 2013 Nov;72(11):1793-9. doi: 10.1136/annrheumdis-2012-202245. Epub 2012 Nov 8.

PMID:
23139265
11.

Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis.

Matsuda J, Kaburaki T, Kobayashi S, Numaga J.

Jpn J Ophthalmol. 2013 Jan;57(1):104-7. doi: 10.1007/s10384-012-0202-z. Epub 2012 Oct 30.

PMID:
23108527
12.

[Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report].

Azevedo VF, Pietrovski CF, de Almeida Santos M Jr.

Reumatismo. 2010 Oct-Dec;62(4):283-5. Review. Italian.

13.

Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.

Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, Wei Q, Zhang YL, Li T, Jin O, Huang J, Pan Y, Wu Y, Deng X, Gu J.

Int J Rheum Dis. 2012 Aug;15(4):358-65. doi: 10.1111/j.1756-185X.2012.01734.x. Epub 2012 May 23. Erratum in: Int J Rheum Dis. 2012 Dec;15(6):564.

PMID:
22898215
14.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

15.

Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis.

Wang H, Zuo D, Sun M, Hua Y, Cai Z.

Int J Rheum Dis. 2014 Feb;17(2):142-8. doi: 10.1111/1756-185X.12245. Epub 2014 Feb 8. Review.

PMID:
24506823
16.

IgG and IgA immune response against klebsiella in HLA-B27-associated anterior uveitis.

Kijlstra A, Luyendijk L, van der Gaag R, van Kregten E, Linssen A, Willers JM.

Br J Ophthalmol. 1986 Feb;70(2):85-8.

17.

A three-centre experience with adalimumab for the treatment of non-infectious uveitis.

Dobner BC, Max R, Becker MD, Heinz C, Veltrup I, Heiligenhaus A, Barisani-Asenbauer T, Mackensen F.

Br J Ophthalmol. 2013 Feb;97(2):134-8. doi: 10.1136/bjophthalmol-2011-301401. Epub 2012 Dec 4.

PMID:
23212204
18.

Bilateral, simultaneous, uveitis-associated pupillary membranes.

Varner P.

Clin Exp Optom. 2011 Sep;94(5):490-3. doi: 10.1111/j.1444-0938.2011.00595.x. Epub 2011 Apr 11.

19.

Anterior uveitis in ankylosing spondylitis: a histocompatibility study.

Scharf J, Nahir M, Scharf J, Brick R, Gidoni O, Barzilai A, Zonis S.

Ann Ophthalmol. 1979 Jul;11(7):1061-2.

PMID:
573580
20.

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F.

J Rheumatol. 2013 Jan;40(1):74-9. doi: 10.3899/jrheum.120583. Epub 2012 Nov 1. Erratum in: J Rheumatol. 2013 Jan;40(1):106.

PMID:
23118110

Supplemental Content

Support Center